BTG (OTCMKTS:BTGGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “
BTGGF traded down $0.38 during trading hours on Friday, reaching $9.14. The company’s stock had a trading volume of 100 shares, compared to its average volume of 2,276. BTG has a fifty-two week low of $7.89 and a fifty-two week high of $10.88.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.